<DOC>
	<DOCNO>NCT00733304</DOCNO>
	<brief_summary>This two month study allow continue treatment pazopanib eye drop . Study may extend 5 month .</brief_summary>
	<brief_title>An Extension Study MD7108240</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Subjects participate Phase IIa study MD7108240 experience AMD disease progression require rescue therapy pazopanib treatment require discontinuation pazopanib eye drop safety reason Bestcorrected ETDRS visual acuity study eye 23 letter ( 20/320 4/63 ) good screen . QTcB QTcF &lt; 450msec ; QTc &lt; 480msec subject Bundle Branch Block . Subject willing able return study visit , willing able comply protocol requirement procedure . Subject capable give write informed consent , include compliance requirement restriction list consent form . If subject unable read consent form due visual impairment consent must read subject verbatim person administer consent , family member legally acceptable representative . If subject unable provide write informed consent due visual impairment , write informed consent behalf subject must provide legally acceptable representative . ( Note : Consent legally acceptable representative allow accordance local law , regulation ethic committee policy . ) Anterior segment vitreous abnormality study eye would preclude adequate observation fundus photograph , fluorescein angiography OCT. Vitreous , subretinal retinal hemorrhage study eye unrelated AMD . Intraocular surgery study eye within 3 month dose . Use topical ocular medication ( pazopanib ) study eye within 7 day first dose investigational product expect use topical ocular medication treatment period , exception artificial tear . Current use medication know toxic retina , lens optic nerve ( e.g . desferoximine , chloroquine/hydrochloroquine , chlorpromazine , phenothiazine , tamoxifen , nicotinic acid , ethambutol ) . An unwillingness refrain wear contact lenses start screen visit , followup visit ALT AST upper limit normal total bilirubin â‰¥ 1.5 time upper limit normal baseline . Note : Laboratory test outside normal range may repeat discretion Investigator . Medical history condition : Uncontrolled Diabetes Mellitus , hemoglobin A1c ( HbA1c ) &gt; 10 % . Myocardial infarction stroke within 6 month screen . Active bleeding disorder . Major surgery within 1 month screening . Hepatic impairment . Uncontrolled hypertension , base criterion provide protocol . Note : Initiation adjustment antihypertensive medication permit prior study entry provide referenced criterion meet . Use prohibit medication list protocol within restrict timeframe relative first dose study medication . A condition situation , opinion investigator , may result significant risk subject , confound study result interfere significantly participation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>vascular endothelial growth factor ( VEGF )</keyword>
	<keyword>choroidal neovascularization ( CNV )</keyword>
	<keyword>age-related macular degeneration ( AMD )</keyword>
	<keyword>pazopanib</keyword>
	<keyword>angiogenesis</keyword>
</DOC>